Plain-English translation of NCT05112601 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , an immunotherapy medication that helps your immune system fight cancer. Some participants will receive alone, while others will receive combined with a second immunotherapy drug called . The study wants to see which approach works better for people with recurring uterine cancer that has a specific genetic characteristic (deficient mismatch repair).
Uterine cancer that comes back after initial treatment is difficult to manage, and current options don't work well for everyone. This medication has shown promise in other cancers, and researchers want to understand whether combining two immunotherapy drugs might be more effective than using one alone for this specific type of recurring cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the single medication or the combination of two medications, given as intravenous infusions every three weeks for up to eight cycles. After that, you will continue with infusions every four weeks for as long as the treatment is working and you are tolerating it well. Throughout the trial, you'll have regular CT or MRI scans, blood tests, and clinic visits to monitor how you're responding and check for side effects. The entire study period could last several months to over a year depending on your response.
AI-generated summary from trial data · Sep 19, 2026 · Not medical advice
United States